A H Wu

Summary

Affiliation: Hartford Hospital
Country: USA

Publications

  1. ncbi The role of cardiac troponin in the recent redefinition of acute myocardial infarction
    Alan H B Wu
    Department of Pathology and Laboratory Medicine, Hartford Hospital, 80 Seymour St, Hartford, CT 06102, USA
    Clin Lab Sci 17:50-2. 2004
  2. ncbi Analysis of the Albumin Cobalt Binding (ACB) test as an adjunct to cardiac troponin I for the early detection of acute myocardial infarction
    A H Wu
    Department of Pathology and Laboratory Medicine, Hartford Hospital, Hartford, CT 06102, USA
    Cardiovasc Toxicol 1:147-51. 2001
  3. ncbi Correlation of polymorphisms to coagulation and biochemical risk factors for cardiovascular diseases
    A H Wu
    Department of Pathology and Laboratory Medicine, Hartford Hospital, Hartford, Connecticut 06102, USA
    Am J Cardiol 87:1361-6. 2001
  4. ncbi Quality specifications in thyroid diseases
    Alan H B Wu
    Department of Pathology and Laboratory Medicine, Hartford Hospital, 80 Seymour St, Hartford, CT 06102, USA
    Clin Chim Acta 346:73-7. 2004
  5. ncbi Long-term follow-up of patients with increased cardiac troponin concentrations following percutaneous coronary intervention
    Alan H B Wu
    Department of Pathology and Laboratory Medicine, Hartford, Connecticut 06102, USA
    Am J Cardiol 89:1300-2. 2002
  6. ncbi Markers for early detection of cardiac diseases
    Alan H B Wu
    Department of Laboratory Medicine University of California, San Francisco, CA, USA
    Scand J Clin Lab Invest Suppl 240:112-21. 2005
  7. ncbi Analytical and clinical evaluation of the Bayer ADVIA Centaur automated B-type natriuretic peptide assay in patients with heart failure: a multisite study
    Alan H B Wu
    Department of Pathology and Laboratory Medicine, Hartford Hospital, 80 Seymour St, Hartford, CT 06102, USA
    Clin Chem 50:867-73. 2004
  8. ncbi Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure
    Alan H B Wu
    Department of Pathology and Laboratory Medicine, Hartford Hospital, Hartford, Connecticut 06102, USA
    Am J Cardiol 92:628-31. 2003
  9. ncbi Evaluation of a point-of-care assay for cardiac markers for patients suspected of acute myocardial infarction
    Alan H B Wu
    Department of Pathology and Laboratory Medicine, Hartford Hospital, 80 Seymour St, Hartford, CT 06102, USA
    Clin Chim Acta 346:211-9. 2004
  10. ncbi Reduced readmission rate for alternating diagnoses of heart failure and pulmonary disease after implementation of B-type natriuretic peptide testing
    Alan H B Wu
    Department of Pathology and Laboratory Medicine, Hartford Hospital, 80 Seymour St, Hartford, CT 06102, USA
    Eur J Heart Fail 6:309-12. 2004

Detail Information

Publications81

  1. ncbi The role of cardiac troponin in the recent redefinition of acute myocardial infarction
    Alan H B Wu
    Department of Pathology and Laboratory Medicine, Hartford Hospital, 80 Seymour St, Hartford, CT 06102, USA
    Clin Lab Sci 17:50-2. 2004
  2. ncbi Analysis of the Albumin Cobalt Binding (ACB) test as an adjunct to cardiac troponin I for the early detection of acute myocardial infarction
    A H Wu
    Department of Pathology and Laboratory Medicine, Hartford Hospital, Hartford, CT 06102, USA
    Cardiovasc Toxicol 1:147-51. 2001
    ..These data indicate a possible role of the ACB test in the early triage of patients with chest pain...
  3. ncbi Correlation of polymorphisms to coagulation and biochemical risk factors for cardiovascular diseases
    A H Wu
    Department of Pathology and Laboratory Medicine, Hartford Hospital, Hartford, Connecticut 06102, USA
    Am J Cardiol 87:1361-6. 2001
    ..The impact of certain genotypes must be examined in relation to other established risk factors and potentially new therapeutic strategies...
  4. ncbi Quality specifications in thyroid diseases
    Alan H B Wu
    Department of Pathology and Laboratory Medicine, Hartford Hospital, 80 Seymour St, Hartford, CT 06102, USA
    Clin Chim Acta 346:73-7. 2004
    ..Given the importance of these measurements, quality specifications are needed to ensure accurate results. Goals for precision and accuracy are available based on known intraindividual and interindividual biological variation...
  5. ncbi Long-term follow-up of patients with increased cardiac troponin concentrations following percutaneous coronary intervention
    Alan H B Wu
    Department of Pathology and Laboratory Medicine, Hartford, Connecticut 06102, USA
    Am J Cardiol 89:1300-2. 2002
  6. ncbi Markers for early detection of cardiac diseases
    Alan H B Wu
    Department of Laboratory Medicine University of California, San Francisco, CA, USA
    Scand J Clin Lab Invest Suppl 240:112-21. 2005
    ..Each of these tests has demonstrated some utility for early diagnosis. However, as most lack specificity for myocardial disease, routine use may require a multi-marker approach...
  7. ncbi Analytical and clinical evaluation of the Bayer ADVIA Centaur automated B-type natriuretic peptide assay in patients with heart failure: a multisite study
    Alan H B Wu
    Department of Pathology and Laboratory Medicine, Hartford Hospital, 80 Seymour St, Hartford, CT 06102, USA
    Clin Chem 50:867-73. 2004
    ..B-Type natriuretic peptide (BNP) is released from the left ventricle of the heart into the circulation in response to ventricular stretching and volume overload. Increased BNP concentrations are associated with heart failure (HF)...
  8. ncbi Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure
    Alan H B Wu
    Department of Pathology and Laboratory Medicine, Hartford Hospital, Hartford, Connecticut 06102, USA
    Am J Cardiol 92:628-31. 2003
    ..This study also shows that there are important differences in the performance of BNP versus NT-proBNP in monitoring patients with congestive heart failure that need to be further explored...
  9. ncbi Evaluation of a point-of-care assay for cardiac markers for patients suspected of acute myocardial infarction
    Alan H B Wu
    Department of Pathology and Laboratory Medicine, Hartford Hospital, 80 Seymour St, Hartford, CT 06102, USA
    Clin Chim Acta 346:211-9. 2004
    ..With new rapid ED assessment protocols, there is increasing pressure to produce results with a short turnaround time (TAT), and point-of-care (POC) testing is one alternative for providing fast results...
  10. ncbi Reduced readmission rate for alternating diagnoses of heart failure and pulmonary disease after implementation of B-type natriuretic peptide testing
    Alan H B Wu
    Department of Pathology and Laboratory Medicine, Hartford Hospital, 80 Seymour St, Hartford, CT 06102, USA
    Eur J Heart Fail 6:309-12. 2004
    ..Effective disease management requires an accurate diagnosis. B-type natriuretic peptide (BNP) is increased in patients with HF and is normal in PD patients without cardiac involvement...
  11. ncbi Biological variation of the natriuretic peptides and their role in monitoring patients with heart failure
    Alan H B Wu
    Department of Pathology and Laboratory Medicine, Hartford Hospital, 80 Seymour St, Hartford, CT 06102, USA
    Eur J Heart Fail 6:355-8. 2004
    ..From these studies, the percent statistical change in serial samples of approximately 100% difference was estimated (95% confidence)...
  12. ncbi Optimum blood collection intervals for B-type natriuretic peptide testing in patients with heart failure
    Alan H B Wu
    Department of Pathology and Laboratory Medicine, Hartford Hospital, Hartford, Connecticut 06102, USA
    Am J Cardiol 93:1562-3. 2004
    ..Samples collected 7 days apart were associated with the highest frequency (50%) of statistically different results (increased or decreased) compared with daily collections, where increased or decreased results occurred less often (22%)...
  13. ncbi Multicenter analytical evaluation of an automated immunoassay for total plasma homocysteine
    A H Wu
    Department of Pathology and Laboratory Medicine, Hartford Hospital, Connecticut 06102, USA
    Ann Clin Lab Sci 30:185-90. 2000
    ..17+/-2.86 micromol/L, with a central 95% range of 4.78-15.43 micromol/L. The immunoassay is a suitable alternative to HPLC and may be useful in screening persons with high risk of coronary artery disease...
  14. ncbi Use of cardiac markers as assessed by outcomes analysis
    A H Wu
    Department of Pathology and Laboratory Medicine, Hartford Hospital, CT 06102, USA
    Clin Biochem 30:339-50. 1997
    ..This article will describe the outcomes studies that have been performed or are needed in relation to biochemical markers in coronary artery diseases (CAD)...
  15. ncbi A comparison of cardiac troponin T and cardiac troponin I in patients with acute coronary syndromes
    A H Wu
    Department of Pathology and Laboratory Medicine, Hartford Hospital, Connecticut 06102, USA
    Coron Artery Dis 10:69-74. 1999
    ..A laboratory is unlikely to purchase an instrument to perform a single test. Because cTnI will soon be available on all commercial immunoassay analyzers, it seems likely that cTnI will become the analyte of choice...
  16. ncbi Reflex testing I: algorithm for lipid and lipoprotein measurement in coronary heart disease risk assessment
    A H Wu
    Clinical Chemistry Laboratory, Hartford Hospital, CT 06102, USA
    Clin Chim Acta 280:181-93. 1999
    ..The algorithm will prevent the overuse of certain expensive tests (direct LDL) while promoting the limited use of underutilized tests [apoB and Lp(a)]...
  17. ncbi Adulteration of urine by "Urine Luck"
    A H Wu
    Department of Pathology and Laboratory Medicine, Toxicology Laboratory, Hartford Hospital, 80 Seymour St, Hartford, CT 06102, USA
    Clin Chem 45:1051-7. 1999
    ..In vitro adulterants are used to invalidate assays for urine drugs of abuse. The present study examined the effect of pyridinium chlorochromate (PCC) found in the product "Urine Luck"...
  18. ncbi Cardiac markers: from enzymes to proteins, diagnosis to prognosis, laboratory to bedside
    A H Wu
    Department of Pathology and Laboratory Medicine, Hartford Hospital, CT 06102, USA
    Ann Clin Lab Sci 29:18-23. 1999
    ..Prospective management of cardiac patients requires more rapid testing and reporting of results. Point-of-care testing platforms on whole blood are now available for emergency testing at bedside...
  19. ncbi Characterization of cardiac troponin subunit release into serum after acute myocardial infarction and comparison of assays for troponin T and I. American Association for Clinical Chemistry Subcommittee on cTnI Standardization
    A H Wu
    Department of Pathology, Hartford Hospital, CT 06102, USA
    Clin Chem 44:1198-208. 1998
    ..However, there are differences in absolute cTnI results due to a lack of mass standardization and heterogeneity in the cross-reactivities of antibodies to various troponin I forms...
  20. ncbi National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendations for the use of cardiac markers in coronary artery diseases
    A H Wu
    Department of Pathology and Laboratory Medicine, Hartford Hospital, Hartford, CT 06102, USA
    Clin Chem 45:1104-21. 1999
    ..At times, the Committee members felt that although a particular recommendation might not be the current standard of care today, they anticipate that it likely will be adopted in the near future...
  21. ncbi Biochemical markers of cardiac damage: from traditional enzymes to cardiac-specific proteins. IFCC Subcommittee on Standardization of Cardiac Markers (S-SCM)
    A H Wu
    Department of Pathology, Hartford Hospital, CT 06102, USA
    Scand J Clin Lab Invest Suppl 230:74-82. 1999
    ..The IFCC S-SCM has recommended use of two cut-off concentrations for cardiac troponin to differentiate normal from minor myocardial injury and AMI. A low cut-off may detect reversible ischemic events in some cases...
  22. ncbi Release of cardiac troponin in acute coronary syndromes: ischemia or necrosis?
    A H Wu
    Department of Pathology and Laboratory Medicine, Hartford Hospital, CT, USA
    Clin Chim Acta 284:161-74. 1999
    ..Jeopardized myocardial tissue can recover with acute recanalization. Support for this model comes from clinical observations and animal studies...
  23. ncbi Reflex testing II: evaluation of an algorithm for use of cardiac markers in the assessment of emergency department patients with chest pain
    A H Wu
    Clinical Chemistry Laboratory, Hartford Hospital, Hartford CT 06102, USA
    Clin Chim Acta 288:97-109. 1999
    ....
  24. ncbi Characteristics of an Albumin Cobalt Binding Test for assessment of acute coronary syndrome patients: a multicenter study
    R H Christenson
    Department of Pathology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Clin Chem 47:464-70. 2001
    ..The ability of the Albumin Cobalt Binding (ACB) Test measurement at presentation to predict troponin-positive or -negative results 6-24 h later was also examined...
  25. ncbi Standardization of cardiac troponin I assays: round Robin of ten candidate reference materials
    R H Christenson
    Department of Pathology, University of Maryland School of Medicine, 22 S Greene St, Baltimore, MD 21201, USA
    Clin Chem 47:431-7. 2001
    ..Cardiac troponin I (cTnI) results vary 100-fold among assays. As a step toward standardization, we examined the performance of 10 candidate reference materials (cRMs) in dilution studies with 13 cTnI measurement systems...
  26. ncbi Standardization of creatine kinase-MB (CK-MB) mass assays: the use of recombinant CK-MB as a reference material
    R H Christenson
    Department of Pathology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Clin Chem 45:1414-23. 1999
    ..The AACC assembled a committee to identify and validate a standard creatine kinase MB isoenzyme (CK-MB) material to improve the comparability of CK-MB mass assays...
  27. ncbi Oral estrogen improves serum lipids, homocysteine and fibrinolysis in elderly men
    S Giri
    Division of Cardiology, Hartford Hospital, CT 06102 5037, USA
    Atherosclerosis 137:359-66. 1998
    ..We conclude that oral estrogen in men reduces homocysteine, fibrinogen, and PAI-1 concentrations and favorably influences VLDL, LDL and HDL subclass levels without increasing markers of thrombotic risk...
  28. ncbi Quantitative determination of cholesterol in lipoprotein fractions by electrophoresis
    J H Contois
    Department of Pathology and Laboratory Medicine, Hartford Hospital, CT 06102, USA
    Clin Chim Acta 282:1-14. 1999
    ..However, HDL cholesterol measurement did not meet NCEP guidelines for precision and accuracy. Also, the poor resolution of VLDL and LDL in some specimens is a concern...
  29. ncbi B-type natriuretic peptide and its clinical utility in patients with heart failure
    A H Wu
    Department of Pathology, Laboratory Medicine, Hartford Hospital, Hartford, CT, USA
    MLO Med Lab Obs 33:10-4; quiz 16, 19. 2001
    ..Table 2 lists some specific areas where BNP might impact the other clinical areas. Outcome studies should be performed to determine if any of these changes in clinical practices can be justified...
  30. pmc A genome screen of families with multiple cases of prostate cancer: evidence of genetic heterogeneity
    C L Hsieh
    University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA, USA
    Am J Hum Genet 69:148-58. 2001
    ..The data provided little support for any of the putative prostate cancer-susceptibility genes identified in other linkage studies...
  31. ncbi Distribution of serum apolipoproteins A-I and B and lipoprotein(a) in European elderly. The SENECA study
    J H Contois
    Department of Pathology and Laboratory Medicine, Hartford Hospital, Hartford, CT, USA
    Clin Chim Acta 295:1-12. 2000
    ..These data show that the elderly in Europe are very heterogeneous with respect to plasma lipoproteins, including apo A-I, apo B, and Lp(a)...
  32. pmc N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease
    Kirsten Bibbins-Domingo
    Department of Medicine, University of California, San Francisco, CA 94143, USA
    JAMA 297:169-76. 2007
    ..Identification of individuals at high risk for cardiovascular events is important for the optimal use of primary and secondary prevention measures...
  33. ncbi Influence of imprecision on ROC curve analysis for cardiac markers
    Peter Kupchak
    Nanogen, Point of Care Diagnostics Division, Toronto, Ontario, Canada
    Clin Chem 52:752-3. 2006
    ..There has been considerable debate regarding the impact of assay imprecision on the performance of cardiac biomarkers for diagnosis of acute coronary syndromes (ACS) and risk stratification for future adverse cardiac events...
  34. ncbi How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. Results from the Breathing Not Properly Multinational Study
    Lori B Daniels
    University of California, San Diego, CA, USA
    Am Heart J 151:999-1005. 2006
    ..We evaluated differential cut-points for BNP in diagnosing acute HF across body mass index levels to determine whether alternative cut-points can improve diagnosis...
  35. ncbi Toward standardization of cardiac troponin I measurements part II: assessing commutability of candidate reference materials and harmonization of cardiac troponin I assays
    Robert H Christenson
    Department of Pathology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Clin Chem 52:1685-92. 2006
    ..Toward this goal, the AACC cTnI Standardization Committee collaborated with the National Institute of Standards and Technology (NIST) in an earlier study to select 2 candidate reference materials (cRMs)...
  36. ncbi National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes
    David A Morrow
    Clin Chem 53:552-74. 2007
  37. ncbi Impact of the history of congestive heart failure on the utility of B-type natriuretic peptide in the emergency diagnosis of heart failure: results from the Breathing Not Properly Multinational Study
    Adam Strunk
    University of California, San Diego, Veterans Affairs San Diego Healthcare System, San Diego, Calif 92161, USA
    Am J Med 119:69.e1-11. 2006
    ..We hypothesized that taking into account the history of congestive heart failure along with other clinical variables would be helpful in this range of B-type natriuretic peptide levels...
  38. ncbi Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results
    Alan H B Wu
    Clinical Chemistry Laboratory, Department of Laboratory Medicine, San Francisco General Hospital, University of California, San Francisco, CA 94110, USA
    Am Heart J 152:828-34. 2006
    ..An assessment of the analytical and biologic variations is necessary to interpret the results of serial testing...
  39. ncbi National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: analytical issues for biochemical markers of acute coronary syndromes
    Fred S Apple
    Clin Chem 53:547-51. 2007
  40. pmc N-terminal pro-B-type natriuretic peptide as a diagnostic test for ventricular dysfunction in patients with coronary disease: data from the heart and soul study
    David C M Corteville
    Department of Medicine, University of California, San Francisco, CA, USA
    Arch Intern Med 167:483-9. 2007
    ..Whether NT-proBNP can be used to detect ventricular dysfunction in patients with stable coronary heart disease (CHD) and no history of heart failure is unknown...
  41. ncbi Cardiac troponin: friend of the cardiac physician, foe to the cardiac patient?
    Alan H B Wu
    Circulation 114:1673-5. 2006
  42. ncbi National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical characteristics and utilization of biochemical markers in acute coronary syndromes
    David A Morrow
    Brigham and Women s Hospital, Harvard University, Boston, MA, USA
    Circulation 115:e356-75. 2007
  43. doi Cross-reactivity of BNP, NT-proBNP, and proBNP in commercial BNP and NT-proBNP assays: preliminary observations from the IFCC Committee for Standardization of Markers of Cardiac Damage
    Kristin N Luckenbill
    Clin Chem 54:619-21. 2008
  44. doi The clinical need for high-sensitivity cardiac troponin assays for acute coronary syndromes and the role for serial testing
    Alan H B Wu
    Department of Laboratory Medicine, Clinical Chemistry Laboratory, San Francisco General Hospital, University of California, San Francisco, CA 94110, USA
    Am Heart J 155:208-14. 2008
    ..Therefore, there is a need to develop troponin assays with higher sensitivity, which cannot be achieved while also improving the assay's precision...
  45. ncbi Development and preliminary clinical validation of a high sensitivity assay for cardiac troponin using a capillary flow (single molecule) fluorescence detector
    Alan H B Wu
    University of California, San Francisco, CA, USA
    Clin Chem 52:2157-9. 2006
  46. ncbi National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical utilization of cardiac biomarker testing in heart failure
    W H Wilson Tang
    Cleveland Clinic, Foundation, Cleveland, OH, USA
    Clin Biochem 41:210-21. 2008
  47. ncbi National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: analytical issues for biomarkers of heart failure
    Fred S Apple
    Hennepin County Medical Center, Minneapolis, MN, USA
    Clin Biochem 41:222-6. 2008
  48. ncbi National Academy of Clinical Biochemistry laboratory medicine practice guidelines: use of cardiac troponin and B-type natriuretic peptide or N-terminal proB-type natriuretic peptide for etiologies other than acute coronary syndromes and heart failure
    Alan H B Wu
    University of California at San Francisco, San Francisco, CA, USA
    Clin Chem 53:2086-96. 2007
  49. ncbi Multi-center validation of the Response Biomedical Corporation RAMP NT-proBNP assay with comparison to the Roche Diagnostics GmbH Elecsys proBNP assay
    Elizabeth Lee-Lewandrowski
    Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Clin Chim Acta 386:20-4. 2007
    ..Point-of-care (POC) assays may provide more timely results and potentially improve patient outcomes...
  50. ncbi Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study
    James L Januzzi
    Department of Medicine and Laboratory Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Am Coll Cardiol 50:607-13. 2007
    ..The aim of this study was to examine the value of measurement of the interleukin-1 receptor family member ST2 in patients with dyspnea...
  51. ncbi National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine practice guidelines: Analytical issues for biomarkers of heart failure
    Fred S Apple
    Hennepin County Medical Center, Minneapolis, Minn, USA
    Circulation 116:e95-8. 2007
  52. ncbi National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure
    W H Wilson Tang
    Circulation 116:e99-109. 2007
  53. ncbi Association between anaemia and N-terminal pro-B-type natriuretic peptide (NT-proBNP): findings from the Heart and Soul Study
    Arati S Desai
    Department of Medicine, Johns Hopkins University, United States
    Eur J Heart Fail 9:886-91. 2007
    ..Anaemia is associated with elevated levels of natriuretic peptides. Whether the association of anaemia with natriuretic peptides is independent of other cardiovascular risk factors is unclear...
  54. ncbi Plasma BNP/NT-proBNP assays: what do they target and what else might they recognize?
    Alan H B Wu
    University of California, San Francisco, CA, USA
    Heart Fail Clin 2:291-8. 2006
  55. ncbi National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: Analytical issues for biochemical markers of acute coronary syndromes
    Fred S Apple
    Hennepin County Medical Center, Minneapolis, MN, USA
    Circulation 115:e352-5. 2007
  56. doi Cardiac troponin and outcome in acute heart failure
    W Frank Peacock
    Department of Emergency Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    N Engl J Med 358:2117-26. 2008
    ..The purpose of our study was to describe the association between elevated cardiac troponin levels and adverse events in hospitalized patients with acute decompensated heart failure...
  57. ncbi B-type natriuretic peptide levels in patients in the emergency department with possible heart failure and previous stable angina pectoris and/or healed myocardial infarction
    James McCord
    Henry Ford Health System, Detroit, Michigan, USA
    Am J Cardiol 96:1370-3. 2005
    ..However, in patients who did not have heart failure, there was a relation between BNP levels and previous stable angina pectoris and/or healed myocardial infarction but no significant independent relation in multiple regression analysis...
  58. ncbi Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay
    Kiang Teck J Yeo
    Department of Pathology, Dartmouth Medical School and Dartmouth Hitchcock Medical Center, 1 Medical Center Drive, Lebanon, NH 03756, USA
    Clin Chim Acta 338:107-15. 2003
    ..Brain natriuretic peptides (BNPs) are useful in the assessment of heart failure, left ventricular dysfunction, and acute coronary syndromes...
  59. ncbi Prognostic value of the Ortho Vitros cardiac troponin I assay in patients with symptoms of myocardial ischemia. Risk stratification using European Society of Cardiology/American College of Cardiology recommended cutoff values
    Fred S Apple
    Department of Laboratory Medicine and Pathology, Hennepin County Medical Center, University of Minnesota School of Medicine, Minneapolis, USA
    Am J Clin Pathol 120:114-20. 2003
    ..08 microgram/L) group for cTnI, with directionally similar results for cTnT. Our findings validate the Ortho cTnI assay as a risk stratification biomarker in patients with symptoms of myocardial ischemia...
  60. ncbi Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study
    Alan S Maisel
    Cardiology 111 A, San Diego VA Medical Center, 3350 La Jolla Village Drive, San Diego, CA 92161, USA
    J Am Coll Cardiol 41:2010-7. 2003
    ..This study examines B-type natriuretic peptide (BNP) levels in patients with systolic versus non-systolic dysfunction presenting with shortness of breath...
  61. ncbi B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study
    Peter A McCullough
    University of California, San Diego Veteran s Affairs Medical Center, San Diego, CA, USA
    Am J Kidney Dis 41:571-9. 2003
    ..However, relationships between BNP, renal function, and heart failure as an emergency diagnosis are unknown...
  62. ncbi Correlation of B-type natriuretic peptide level to 6-min walk test performance in patients with left ventricular systolic dysfunction
    Stacey J Wieczorek
    Department of Pathology and Laboratory Medicine, Hartford Hospital, 80 Seymour St, Hartford, CT 06102, USA
    Clin Chim Acta 328:87-90. 2003
    ..We compared whole blood BNP concentrations to distance walked during a 6-min walk test in patients with CHF...
  63. ncbi European Society of Cardiology and American College of Cardiology guidelines for redefinition of myocardial infarction: how to use existing assays clinically and for clinical trials
    Fred S Apple
    Department of Laboratory Medicine and Pathology, Hennepin County Medical Center and University of Minnesota School of Medicine, Minneapolis, Minn, USA
    Am Heart J 144:981-6. 2002
    ..The Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation (COURAGE) trial asked for recommendations concerning the use of troponin assays for the trial...
  64. ncbi A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: a multicenter evaluation
    Stacey J Wieczorek
    Department of Pathology and Laboratory Medicine, Hartford Hospital, Hartford, Conn, USA
    Am Heart J 144:834-9. 2002
    ....
  65. ncbi B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study
    Peter A McCullough
    University of California, Veteran s Affairs Medical Center, San Diego, USA
    Circulation 106:416-22. 2002
    ..We sought to determine the degree to which B-type natriuretic peptide (BNP) adds to clinical judgment in the diagnosis of congestive heart failure (CHF)...
  66. ncbi Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure
    Alan S Maisel
    University of California, San Diego, Veterans Affairs Medical Center, San Diego 92161, USA
    N Engl J Med 347:161-7. 2002
    ..B-type natriuretic peptide is released from the cardiac ventricles in response to increased wall tension...
  67. ncbi Cardiac markers: cost-effective triage for MI admission and therapy
    Alan H B Wu
    Department of Pathology and Laboratory Medicine, Hartford Hospital, Hartford, CT, USA
    MLO Med Lab Obs 34:36-40. 2002
  68. ncbi Evaluation of imprecision for cardiac troponin assays at low-range concentrations
    Mauro Panteghini
    Laboratorio Analisi Chimico Cliniche 1, Azienda Ospedaliera Spedali Civili, 25125 Brescia, Italy
    Clin Chem 50:327-32. 2004
    ..Pools of human sera containing cardiac troponin concentrations around the MI decision limit were assessed to identify the lowest concentration associated with a 10% CV...
  69. ncbi Standardization of immunoassays for measurement of myoglobin in serum. Phase I: evaluation of candidate secondary reference materials
    Mauro Panteghini
    Laboratorio Analisi Chimico Cliniche 1, Azienda Ospedaliera Spedali Civili, 25125 Brescia, Italy
    Clin Chim Acta 341:65-72. 2004
    ..Its concentrations in serum can be measured by immunoassays and are used as an early indicator of myocardial necrosis. Since variability among commercial myoglobin assays exists, standardization of myoglobin assays is needed...
  70. ncbi Diagnostic value of B-Type natriuretic peptide and chest radiographic findings in patients with acute dyspnea
    Cathrine W Knudsen
    Ulleval University Hospital, Oslo, Norway
    Am J Med 116:363-8. 2004
    ..To compare chest radiographic findings and circulating B-type natriuretic peptide (BNP) levels as an adjunct to clinical findings in the diagnosis of heart failure in patients presenting with acute dyspnea...
  71. ncbi Relationship of B-type natriuretic peptide and anemia in patients with and without heart failure: a substudy from the Breathing Not Properly (BNP) Multinational Study
    Alan H B Wu
    Department of Laboratory Medicine, University of California, San Francisco, San Francisco General Hospital, 1001 Potrero Ave, California 94110, USA
    Am J Hematol 80:174-80. 2005
    ..Among systolic HF patients, the presence of a low hemoglobin concentration is not a factor in the interpretation of BNP results...
  72. ncbi Validation of the 99th percentile cutoff independent of assay imprecision (CV) for cardiac troponin monitoring for ruling out myocardial infarction
    Fred S Apple
    Hennepin County Medical Center and University of Minnesota School of Medicine, Minneapolis, 55415, USA
    Clin Chem 51:2198-200. 2005
  73. ncbi Impact of atrial fibrillation on the diagnostic performance of B-type natriuretic peptide concentration in dyspneic patients: an analysis from the breathing not properly multinational study
    Cathrine Wold Knudsen
    Ulleval University Hospital, Oslo, Norway
    J Am Coll Cardiol 46:838-44. 2005
    ....
  74. ncbi Predictors of elevated B-type natriuretic peptide concentrations in dyspneic patients without heart failure: an analysis from the breathing not properly multinational study
    Cathrine W Knudsen
    University of California, San Diego, Veteran s Affairs Medical Center, San Diego, CA, USA
    Ann Emerg Med 45:573-80. 2005
    ..The objective of the current study was to identify independent predictors of elevated BNP concentrations in the absence of congestive heart failure...
  75. ncbi Comparative sensitivities between different plasma B-type natriuretic peptide assays in patients with minimally symptomatic heart failure
    W H Wilson Tang
    Department of Cardiovascular Medicine, Section of Heart Failure and Cardiac Transplantation Medicine, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Clin Cornerstone 7:S18-24. 2005
    ..These findings suggest that there is a relationship between the decision statistics used in screening for left ventricular dysfunction and the type of diagnostic assay used...
  76. ncbi Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome
    Fred S Apple
    Department of Laboratory Medicine and Pathology, Clinical Laboratories, Hennepin County Medical Center, Minneapolis, MN 55415, USA
    Clin Chem 51:810-24. 2005
    ....
  77. ncbi Quality specifications for B-type natriuretic peptide assays
    Fred S Apple
    Department of Laboratory Medicine and Pathology, Hennepin County Medical Center, Minneapolis, MN 55415, USA
    Clin Chem 51:486-93. 2005
    ....
  78. ncbi The effect of diabetes on B-type natriuretic peptide concentrations in patients with acute dyspnea: an analysis from the Breathing Not Properly Multinational Study
    Alan H B Wu
    Department of Pathology and Laboratory Medicine, Hartford Hospital, Connecticut, USA
    Diabetes Care 27:2398-404. 2004
    ..We determined the effect of diabetes on B-type natriuretic peptide (BNP) concentrations in patients presenting to the emergency department with dyspnea...
  79. ncbi Impact of age, race, and sex on the ability of B-type natriuretic peptide to aid in the emergency diagnosis of heart failure: results from the Breathing Not Properly (BNP) multinational study
    Alan S Maisel
    University of California, San Diego, Veteran s Affairs Medical Center, San Diego, Calif 92161, USA
    Am Heart J 147:1078-84. 2004
    ..B-type natriuretic peptide (BNP) is secreted from the cardiac ventricles in response to increased wall tension...
  80. ncbi Uncovering heart failure in patients with a history of pulmonary disease: rationale for the early use of B-type natriuretic peptide in the emergency department
    Peter A McCullough
    William Beaumont Hospital, Royal Oak, MI 48073, USA
    Acad Emerg Med 10:198-204. 2003
    ..Heart failure, asthma, and chronic obstructive pulmonary disease (COPD) are syndromes where dyspnea and wheezing are overlapping signs, and hence, these syndromes are often difficult to differentiate...
  81. ncbi Multicenter evaluation of an automated assay for troponin I
    Denise Uettwiller-Geiger
    John T Mather Memorial Hospital, Port Jefferson, NY 11777, USA
    Clin Chem 48:869-76. 2002
    ..We describe an assay that overcomes problems of early assays that were often affected by cTnI degradation, assay interference, poor sensitivity, and imprecision...